Gut microbiota and dynamics of ammonia metabolism in liver disease

ABSTRACT Blood ammonia levels in healthy individuals are low, but they increase in liver disease due to loss of functional liver mass and portosystemic shunting. Hyperammonemia is one of the

key factors involved in the prognosis of cirrhosis and its complications. Here we review to establish a connection between alterations in gut microbial communities and intestinal ammonia

metabolism, highlighting a key impact of gut dysbiosis on blood ammonia levels during liver disease. SIMILAR CONTENT BEING VIEWED BY OTHERS GUT MICROBIOTA ANALYSIS IN CIRRHOSIS AND

NON-CIRRHOTIC PORTAL HYPERTENSION SUGGESTS THAT PORTAL HYPERTENSION CAN BE MAIN FACTOR OF CIRRHOSIS-SPECIFIC DYSBIOSIS Article Open access 11 March 2025 IMPAIRED FLUX OF BILE ACIDS FROM THE

LIVER TO THE GUT REVEALS MICROBIOME-IMMUNE INTERACTIONS ASSOCIATED WITH LIVER DAMAGE Article Open access 07 June 2023 UTILIZING THE GUT MICROBIOME IN DECOMPENSATED CIRRHOSIS AND

ACUTE-ON-CHRONIC LIVER FAILURE Article 30 November 2020 INTRODUCTION The gut microbiome dynamically interacts with the human physiology to maintain the integrity of the intestinal

microecosystem. The metabolism of ammonia is influenced by both the host’s intestinal metabolic machinery and the gut microbial community1. The liver primarily catabolizes ammonia and in

conjunction with other organs plays a crucial role in controlling its level in the bloodstream. When ammonia metabolism (both production and clearance) in the intestine, liver, or other

organs is disturbed, for example in liver diseases, its levels in the blood are elevated (known as hyperammonemia) and this can have deleterious effects, particularly leading to

complications such as increased hospitalization and hepatic encephalopathy (HE)2. While it has been widely accepted that an imbalance in gut bacteria plays a significant role in the

development and advancement of liver disease, the connections between the gut microbiome and the metabolism of ammonia remain understudied. Here, we highlight the significance of gut

microbiota in the production and consumption of ammonia and make an effort to link changes in gut microbial populations to ammonia metabolism and levels in liver diseases. In this review, we

would be discussing ammonia metabolism in chronic liver disease and cirrhosis and not ACLF or ALF. AMMONIA METABOLISM IN HEALTH AND DISEASE SYNTHESIS OF AMMONIA IN HEALTH Ammonia is an

important metabolite that maintains cellular pH. In nature, ammonia exists in gaseous and ionic form as ammonium ion (NH4+), which are in equilibrium with each other. Recently, it has been

shown that an NH4+ uses transporters to transverse the cell membrane, where it first dissociates into ammonia and hydrogen ion (a proton), which then pass through the cell membrane and then

finally both again combine into NH4+ inside the cell3. The blood levels of ammonia must remain very low because even slightly elevated concentrations are toxic to the central nervous

system4. In healthy humans, blood ammonia levels are maintained in the range of 10–40 μM5. Most of the ammonia in circulation originates from the gastrointestinal tract from the catabolism

of dietary proteins and amino acids. Among all amino acids, glutamate and glutamine are most prominent players of nitrogen and ammonia metabolism6. In the intestine, ammonia is primarily

produced through two processes. Firstly, it is formed when glutamine is deaminated by phosphate activated glutaminase (PAG) in the enterocytes lining the mucosal layer of small intestine and

colon. Secondly, it is generated from the conversion of dietary urea (protein rich foods) or hepatic urea (15–30%) by the gut microbial urease enzyme, which is abundant in the colon7 (Fig.

1a). In healthy individuals, ~80% of intestinal PAG is located in the small intestine, whereas the remaining 20% is found in the large intestine8. During the post-absorptive state, as seen

in dogs, approximately 50% of intestinal ammonia originates from metabolism of glutamine in small intestine, 21% comes from breakdown of urea in the large intestine while 5% comes from

glutamine metabolism in large intestine9. The kidneys also play a role in ammonia production by means of PAG majorly in renal epithelial cells in the proximal tubule. During the

post-absorptive stage, glutamine coming from the liver serves as the primary substrate for renal production of ammonia through the action of PAG10. Along with ammonia, kidneys also produce

equimolar bicarbonate generation (two NH4+ and two bicarbonate molecules). Thus, ammonia metabolism in the kidneys is critical to maintain acid base homeostasis11. SYNTHESIS OF AMMONIA IN

LIVER DISEASE Arterial ammonia levels in patients with liver disease range from 40–60 μM in cirrhosis. Changes in arterial ammonia levels are better indicators of liver disease as they are

representative of changes in urea cycle enzymes in liver as compared to venous ammonia levels, which are less accurate because of peripheral uptake of ammonia into muscle and brain tissue12.

Studies have shown that elevated intestinal PAG activity plays a significant role in enhanced systemic blood ammonia or hyperammonemia during liver disease (Fig. 1b). Preclinical

investigations have reported that duodenal PAG activity in mucosal biopsies of the small intestine increase by almost four times in cirrhotic patients compared to healthy individuals8.

Studies have shown that hyperammonemia is primarily caused by preexisting intra- and/or extrahepatic portacaval shunts (that directly connect portal to systemic blood) in rats with

cirrhosis. Several studies have proven that portal-systemic shunting is the major cause of elevated ammonia levels in the systemic circulation. This has also been shown in stable individuals

with cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt). In comparison to controls, both portal and arterial ammonia increases substantially after portacaval shunting13,14.

The hepatic extraction efficiency of ammonia from the portal vein is about 93%in health15. Thus, little, if any, ammonia enters the systemic circulation from the portal vein under normal

conditions, and the liver maintains the level of circulating ammonia at relatively low levels. Ammonia extraction is reduced in the presence of portosystemic shunting16. This is attributed

to a predominance of pathobionts within the gut microbiome that produces more ammonia irrespective of the degree of portosystemic shunting17. The microbiome also contributes towards

increased synthesis of intestinal ammonia through the action of the bacterial enzymes18. Studies have demonstrated that in patients with advanced cirrhosis and upper gastrointestinal

bleeding, kidneys have a six-fold increase in ammonia production due to increased alanine uptake19. However, it has also been shown in experimental and clinical studies that kidneys remove

more ammonia from the body than its production following hyperammonemia induced by portacaval shunting14. AMMONIA REMOVAL IN HEALTH LIVER Ammonia is efficiently detoxified in the liver

through either the conversion into urea via the urea cycle enzymes or the conversion into glutamine through the activity of glutamine synthetase (GS) (Fig. 1a, c). The enzymes responsible

for the urea cycle are mainly found in periportal hepatocytes, whereas GS is significantly abundant in perivenous hepatocytes20. The initial stage of the urea cycle is controlled by the

enzyme carbamoyl phosphate synthetase I (CPS I), which acts as a rate-limiting enzyme. In the first stage, carbamoyl phosphate and ornithine react together, resulting in the production of

citrulline which in further stages with the help of other enzymes, produces urea21 (Fig. 1c). Urea is passively transported across the biological membranes by diffusion and with the help of

urea transporters, it is ultimately removed by the kidneys in the urine22. The perivenous hepatocytes convert ammonia to glutamine by GS, thus providing an alternate method for scavenging

ammonia20. Hepatic glutamine metabolism, together with urea synthesis, has a vital role in maintaining the detoxification of ammonia in the body23. MUSCLES In addition to the liver, GS

activity is also found in the muscles, but it is lower compared to the liver during health. By employing genetic methods to completely eliminate GS from muscle, it has been demonstrated that

GS has a minimal role in muscle during normal fed conditions, and only becomes significant during times of stress, such as starvation or hyperammonemia24. BRAIN The brain exhibits GS

activity majorly in astrocytes and some in the neurons, rendering it an essential organ for detoxification and utilization of ammonia in the maintenance of a healthy state25. Astrocyte GS

utilizes ammonia in order to produce glutamine, which is subsequently delivered to neurons for deamination to produce crucial neurotransmitters glutamate and GABA26. KIDNEYS The kidneys

closely regulate the elimination of urinary ammonia by many mechanisms, including tubular urine flow, apical/basolateral ion exchangers (such as Na + –K + –NH4 + –ATPase), acid-base balance,

and ammonia counter-current system27. The regulation of ammonia transport by renal epithelial cells determines the amount of ammonia that is excreted in urine or returned to the systemic

circulation. Under basal conditions, 30% of the ammonia that is produced in kidneys is excreted in urine and 70% is added to the systemic circulation via renal veins10. AMMONIA REMOVAL IN

DISEASE LIVER Chronic liver disease causes a decreased clearance of ammonia in liver. A decline in the expression and activity of urea cycle enzymes leads to hyperammonemia28 (Fig. 1c). In

cirrhosis, the loss of hepatocytes results in a significant reduction in the liver’s capacity to detoxify ammonia through the urea cycle or GS activity29 (Fig. 1b). However, generally there

is enough capacity to remove ammonia from the body until the emergence of advanced chronic liver disease. Many patients with stable cirrhosis show normal systemic ammonia levels, indicating

that the liver is still capable of efficiently removing majority of ammonia from the portal vein and hepatic artery. This is also evident by the fact that a large increase in protein intake

in patients with cirrhosis enhances functional hepatic nitrogen clearance and urea synthesis30. During advanced liver disease, reduced hepatic clearance, and presence of portal-systemic

shunting, are important causes of hyperammonemia9,29. Using a 90 min constant infusion of ammonia to achieve plasma steady-state, Eriksen et al. clearly demonstrated that in patients with

cirrhosis, ammonia clearance was ∼20% lower and ammonia production nearly threefold higher than in healthy persons, indicating relevance of both ammonia clearance and production in governing

plasma ammonia levels29. KIDNEYS During liver cirrhosis and portocaval shunting, kidneys respond to early hyperammonemia by enhancing ammonia excretion in the urine (70%) and decreasing its

secretion into the renal vein (30%)14. The improvement of renal ammonia excretion following TIPS and the decrease in renal ammonia release into circulation in patients with cirrhosis

provide supporting evidence for this19. Changes in urinary ammonia excretion can result from changes in renal epithelial cell ammonia transport that determines the proportion that is

excreted in the urine versus that delivered to systemic circulation10. MUSCLES Due to the presence of GS activity, muscle is considered as a good buffer system to dispose of excess

circulating ammonia during liver disease. GS activity in muscles is known to increase during hepatic insufficiency and portosystemic shunting31. Cirrhotic patients with a normal muscle mass

may experience a less severe form of hyperammonemia while those having significant muscular atrophy are more susceptible to developing hyperammonemia13. The relationship between

hyperammonemia and muscle mass is complex. Hyperammonemia is known to have a direct negative effect on muscle turnover by causing an increased activation of myostatin (an inhibitor of muscle

growth), mitochondrial dysfunction with decreased ATP content, modifications of contractile proteins, and impaired ribosomal function32. Sarcopenia (reduced muscle mass and strength), that

is present between 30% and 70% of cirrhotic patients and low myostatin levels have been independently associated with the development of HE33. Also, due to excessive protein catabolism in a

sarcopenic muscle, glutamine synthesis by GS may be decreased and hence cirrhotic patients with sarcopenia will have a reduced GS activity and a higher risk of developing HE34,35. In

addition, it is important to note that the process of skeletal muscle ammonia uptake and glutamine release does not always result in overall detoxification of ammonia in the body. This is

because the glutamine produced by the muscles can be absorbed by the splanchnic area or kidneys and converted back into ammonia, which is then released into the bloodstream36. Maintaining an

optimum muscle mass by light exercise and increased caloric intake have been shown to be beneficial in patients with compensated cirrhosis in a few studies but long-term clinical effects in

patients with hyperammonemia need to be clarified further36. BRAIN Enhanced ammonia detoxification via the conversion of glutamate to glutamine by brain GS results in elevated levels of

glutamine, causing osmotic stress and subsequent cell swelling. Brain glutamine levels correlate with the grade of HE in patients with cirrhosis37. The underlying pathophysiology of HE in

cirrhosis is multifactorial, involving accumulation of ammonia and manganese in brain, systemic and central inflammation, activation of the GABAergic neurotransmitter system, etc. Astroglial

and microglial cells are the major cells affected during HE in cirrhosis patients38. GUT MICROBIOME IN LIVER DISEASE Microbial species have been identified in several parts of the gut, such

as the mucosa-associated microbiota (intestinal biopsies) and the luminal or stool microbiota, using 16S rRNA gene sequencing39,40. The mucosal microbiota, located within the mucus layer

that adheres to the mucosa, differs from and remains more consistent throughout time compared to the luminal counterpart. In contrast to luminal or stool microbiota, the mucosal microbiota

engages more closely with the host. Therefore, changes in the stool microbiota may not provide an adequate representation of the complex interactions that take place immediately at the

surface of the gut mucosa. Nevertheless, because of the challenge of acquiring mucosal microbiota, most of the studies have opted for stool sampling as a means of screening microbiota40. Gut

and stool microbiota have been linked to the progression of almost all liver diseases, regardless of their etiology41. GUT MICROBIOTA AND AMMONIA METABOLISM The gut microbiota is

intricately linked to the processes of nitrogen and ammonia metabolism, and any modifications in the microbiome can cause major disturbances that ultimately impact the entire system. The

small intestinal lumen harbors a substantial number of live bacteria, but this number is even higher in the large intestine. Small intestinal microbiota plays an important role in metabolism

of nitrogen and ammonia. Dietary and endogenous proteins are a potential source of amino acids for the microbiota. These amino acids are utilized by the bacteria for protein synthesis,

production of metabolic energy, and recycling of reduced co-factors42. Our understanding of ammonia metabolism by the microbiota in the small intestine remains limited in comparison to the

large intestine or colon. Hence, in this review, we have restricted our discussion to the large intestine only. In healthy individuals, the concentration of ammonia in the lumen of large

intestine is typically low due to the presence of low pH and high amounts of carbohydrates which prevent the synthesis of ammonia40. AMMONIA PRODUCTION BY MICROBIAL UREASE ACTIVITY Several

gut microbial species in the colon are involved in the production of ammonia, either through the conversion of urea by bacterial urease or through proteolysis activities. Urease is an

enzymatic protein synthesized by bacteria that facilitates the conversion of urea into carbamate and ammonia. Mammals do not possess any identified urease gene, therefore, the process of

urea breakdown in the colon, facilitated by urease, is dependent only on the gut microbiota43,44. Urea transporters are found in the colonic mucosa and are involved in delivering dietary or

systemic urea from the bloodstream to the intestinal lumen45. The majority of the bacteria that produce urease are mainly Gram-negative facultatively anaerobic bacteria belonging to the

Enterobacteriaceae and Veillonellaceae families. _Klebsiella pneumoniae_, a member of the Enterobacteriaceae family, has demonstrated significant urease activity in the in vitro

investigations. In addition, it is worth noting that anaerobic gram-positive bacteria, such as Streptococcaceae, possess significant urease activity46. More than 90% of clinical strains of

methicillin-resistant gram-positive bacteria, _Staphylococcus aureus_ also have the ability to break down urea by hydrolysis. The significance of urease in facilitating bacterial survival in

hostile microenvironments within the host’s body is particularly evident in the instance of _Helicobacter pylori_ (_H pylori_), a pathogen accountable for gastritis and peptic ulcers, which

maintains its activity at the pH of stomach. _H. pyrloi_ possesses the ability to produce ammonia as a result of its urease activity47. They demonstrate a markedly higher level of urease

activity as compared to numerous other members of the Enterobacteriaceae family48. Studies have shown that _H. pylori_ increases the generation of ammonia in laboratory conditions and in rat

models of cirrhosis. While there has been extensive research on urease activity in _H. pylori_, there is limited evidence on urease activities in other bacterial species found in the large

intestine49. The existence of commensal bacteria possessing urease activity, which generates endogenous ammonia, implies a crucial role of ammonia generation in physiological processes

conducted an excellent study that reported an advantageous function of naturally occurring ammonia synthesis by gut urease bacteria (Figure 2). A strain of urease-expressing bacteria, called

_Streptococcus thermophilus_, was found to reverse depression-like behaviors in mice. When the production of ammonia in the gut was blocked by inhibiting the activity of urease-producing

bacteria, it increased vulnerability to stress49, indicating the significance of urease bacteria in maintaining ammonia levels for physiological functions. AMMONIA PRODUCTION BY MICROBIAL

PROTEOLYTIC ACTIVITY In addition to urease, a variety of bacterial species in the colon produce ammonia by proteolytic activities. The primary organisms responsible for the breakdown of

proteins in the large intestine are the _Bacteroides, Clostridium, Propionibacterium, Fusobacterium, Streptococcus_, and _Lactobacillus_ genera. _Bacteroides_ species, including _Bacteroides

vulgatus_ and _Bacteroides fragilis_, release proteases in the intestines50 (Fig. 2). Vince et al. isolated specific proteolytic bacteria from healthy subjects and tested their ability to

produce ammonia. The study found that the bacteria responsible for ammonia production were primarily gram-negative anaerobic and aerobic rods, such as _Clostridia_, Bacillus spp, some

_Helicobacter sp., Mycobacterium TB, Mycobacterium bovis_, and _Vibrio parahaemolytic_. Research has shown that microbial proteases play a role in disorders such as inflammatory bowel

disease (IBD) and irritable bowel syndrome (IBS)51, however, their role in cirrhosis remains completely unexplored. In cirrhosis, a study by Kang et al. observed that in the large intestine,

PAG activity was decreased in germ-free cirrhotic mice as compared to conventional cirrhotic mice indicating that PAG activity is contributed by both host and gut microbiota. In the large

intestine and cecal lining of conventional cirrhotic mice, they also reported an increased abundance of _Staphylococcaceae, Enterobacteriaceae_, and _Lactobacillaceae_ and lower abundance of

indigenous families like _Lachnospiraceae, Ruminococcaceae, Clostridiales XIV_ and _Bifidobacteriaceae_. Although the proteolytic or urease activities of these bacteria were not studied,

the relative abundance of these bacterial families was positively correlated with increased systemic ammonia and neuroinflammation52. GUT MICROBIOTA AND AMMONIA PRODUCTION IN CIRRHOSIS AND

HE Pyrosequencing of the 16S rRNA V3 region has shown that the composition of the stool microbiota in the cirrhosis patients varies in terms of both phyla and families. The families

Enterobacteriaceae, Veillonellaceae (Gram-negative facultative anaerobic bacteria), and Streptococcaceae (anaerobic gram-positive bacteria) are commonly found in patients with cirrhosis at

the family level. A positive correlation has been identified between the Child-Turcotte-Pugh (CTP) score and Streptococcaceae in patients with cirrhosis53. Rai et al. revealed a positive

correlation between the severity of cirrhosis as measured by the Model for End Stage Liver Disease (MELD) score, and the presence of the harmful gut bacterial phylum, Enterobacteriaceae.

Conversely, a negative correlation between the severity of cirrhosis and the presence of Ruminococcacea in the gut was seen54. In cases of more severe liver diseases such as acute-on-chronic

liver failure (ACLF), it has been observed that the presence of harmful bacterial families, specifically Proteobacteria, Enterococcaceae, and Streptococcaceae, is associated with greater

mortality and poor outcomes55. Although no quantitative correlations have been done, yet the presence of increased abundance of gut bacterial families such as Veillonellaceae and

Streptococcaceae has been suggested to correlate with increased production of gut ammonia in cirrhosis53. An increase in ammonia production in the large intestine during cirrhosis can be

attributed to a decrease in the presence of beneficial commensal bacteria and the generation of short-chain fatty acids and organic acids. These substances increase the pH of the large

intestine, which in turn enhances bacterial metabolism and leads to an increase in ammonia production. Alterations in the microbiota during cirrhosis can also lead to modifications in the

process of bacterial nitrogen assimilation. A majority of gut bacteria have the ability to manufacture glutamate dehydrogenase and utilize ammonium in their metabolic pathways, allowing many

gut symbionts to ingest ammonium56. This is important for detoxification since high levels of ammonium can be detrimental to both microbiota and host. Some of the bacterial taxas which are

known to be utilizing ammonia for their metabolic activities are Bacillus, Clostridium, Pseudomonas, Streptomyces, Bacteroides, Methanobacteria57,58. However, as of date, there is limited

knowledge of the specific relationship between the type and quantity of gut bacteria and the generation or utilization of intestinal ammonia in cirrhosis (Fig. 2). Given the prominent role

of ammonia in the development of HE, several studies have investigated gut microbial changes in patients with HE. HE has been classified into two categories based on the severity of

symptoms: overt HE (OHE), which is fully symptomatic, and a less symptomatic state known as minimal HE (MHE)54. The main pathophysiological mechanism of OHE and MHE is hyperammonemia leading

to astrocyte dysfunction and deficits in some cognitive areas that can only be measured by neuropsychometric testing. Psychometric and behavioral changes are present with lesser or no

symptoms in MHE but hyperammonemia exists in both conditions59. The gut microbiome of cirrhotic individuals with MHE has a significant increase in _Escherichia coli_ and _Staphylococcus

spp_. compared to patients without MHE60. Zhang et al. identified distinct changes in patients with cirrhosis and MHE, including a higher abundance of _Streptococcus salivarius_ compared to

those without MHE. Remarkably, a direct association between the prevalence of _Streptococcus salivarius_ and the accumulation of ammonia in cirrhotic individuals with MHE was also seen61.

Another study demonstrated the presence of urea catabolite genes in _Streptococcus salivarius_, which were associated with increased activity of the urease enzyme. Therefore, the connection

between _Streptococcus salivarius_ and hyperammonemia in individuals with minimal hepatic encephalopathy (MHE) could be attributed to the significant urease activity exhibited by these

bacteria59. In another study, it was discovered that the presence of Alcaligeneceae (Gram-negative, aerobes) and Porphyromonadaceae (gram-negative anaerobes) in stool was positively

correlated with cognitive impairment in patients with cirrhosis. Importantly, the link between HE and cognitive impairment was attributed to the capacity of Alcaligenaceae to produce ammonia

through the breakdown of urea47. GUT MICROBIOTA-TARGETED AMMONIA-LOWERING THERAPIES Although not many studies have evaluated the contribution of gut microbiota to ammonia production in HE

and cirrhosis pathogenesis, interestingly, most of the successful ammonia-lowering therapies in HE are either based on changing the pH of the gut or modulating the gut microbiota. Since

hyperammonemia is associated with HE in patients with cirrhosis, here we discuss these therapies in context of HE. LACTULOSE Lactulose is a synthetic sugar that is not broken down by the

body until it reaches the colon. In the colon, it gets converted by bacteria into acetic acid and lactic acid. These carboxylic acids lower the pH inside the colon, inhibit the growth and

metabolism of urease bacteria, thus reducing ammonia production62. Lactulose also reduces ammonia and other nitrogenous substances from the colon by its cathartic action (which is probably

caused by the osmotic effect of the organic acid metabolites of lactulose solution) that expels the trapped ammonium ions63. Lactulose also results in dose-dependent acceleration of the

colonic transit time64. Lactulose behaves as a prebiotic and modifies the composition of the intestinal microbiota through an increase in beneficial bacteria (e.g., _Bifidobacteria_ and

_Lactobacillus_) and a decrease in potentially harmful bacteria (e.g., Enterobacteria) thereby contributing to healthier intestinal microbiota in patients with cirrhosis65. It would be

worthwhile to study the type of gut bacteria being modulated by lactulose treatment and their relation with intestinal ammonia metabolism. PROBIOTICS Probiotic therapy entails oral

administration of live microorganisms, either monocultures or mixed cultures, with the aim of enhancing beneficial properties of the intestinal microflora62. Several studies have provided

evidence that native and engineered probiotics profoundly affect many aspects of intestinal nitrogen metabolism (production or utilization) that reduce the production of ammonia in the gut

and hence hyperammonemia. In order to reduce the amount of intestinal ammonia production, Kurtz et al. modified the probiotic _Escherichia coli Nissle_ 1917 to generate a new strain called

SYNB1020 (S-ARG) by upregulating arginine biosynthesis by removing a negative regulator of l-arginine biosynthesis and adding a feedback-resistant enzyme involved in l-arginine biosynthesis.

When ingested, this novel variant had the capability to convert ammonia (NH3) into l-arginine. The SYNB1020 in vitro system demonstrated enhanced l-arginine synthesis from ammonia. SYNB1020

illustrated efficacy in reducing systemic hyperammonemia, enhancing survival in ornithine transcarbamylase-deficient mice, and reducing hyperammonemia in thioacetamide-induced liver injury

mouse models66. SYNB1020 was safe but could not lower blood ammonia in patients with cirrhosis in a phase 1b/2a trial. In another study by Sanchez et al., the efficacy of genetically

engineered _E.coli Nissle_ strains (S-ARG and S-ARG + BUT) was studied on HE. S-ARG + BUT strain along with converting ammonia to arginine, also synthesized butyrate, effectively attenuated

hyperammonemia and prevented memory impairment in bile duct ligated rats67. Another study showed that genetically engineered _Lactobacillus plantarum_ strain exhibited exceptional efficacy

in converting ammonia to alanine (NH3 hyperconsuming strain) and had significant effects on reducing levels of ammonia in the blood and feces68. ANTIBIOTICS Oral antibiotics have been

commonly used to specifically target pathogenic bacteria in the colon. Neomycin and vancomycin are antibiotics that have been proven to reduce blood ammonia levels in patients suffering from

end-stage liver disease7. Neomycin is known to reduce the endogenous production of ammonia and is used for treatment of acute or acute on chronic HE69. Vancomycin has been shown to reduce

blood ammonia and also the severity of HE in patients with cirrhosis70. Another antibiotic, rifaximin that is poorly absorbed in the blood and primarily targets gut bacteria, reduces the

formation of ammonia in HE71. A randomized, double-blind research showed that the antibiotic rifaximin effectively attenuates HE by reducing arterial blood ammonia, improving in asterixis in

patients with chronic liver disease72. Prophylactic administration of rifaximin has shown to improve hyperammonemia and prevent neurophysiological functions in patients with cirrhosis by

modulation of metabolic activity of gut bacteria73. FECAL MICROBIOTA TRANSPLANTATION (FMT) FMT involves the transfer of stool from a donor who has a healthy gut microbiota to a patient who

has an imbalanced gut microbiota, with the goal to restore healthy microbiome. A healthy donor is considered the one with no active infections and antibiotics usage within 3 months of

enrollment, obesity, diabetes, chronic alcohol intake, IBD, CKD, or any other malignancy74. The administration of FMT led to a decrease in hospitalizations and improved cognitive skills in

patients with cirrhosis who experienced repeated episodes of HE75. In patients with advanced cirrhosis, FMT decreased microbial-associated ammonia production and augmented ammonia

utilization via anaerobic metabolism of L-aspartate to Hippurate (glycine conjugate of benzoic acid) providing concrete evidence of gut microbiome’s contribution towards altered ammonia

metabolism in cirrhosis. Hippurate is a marker of gut diversity, associated with microbial degradation of certain dietary components, and is known to facilitate the disposal of ammonia by

urinary excretion76. ENGINEERED MICROBIOTA AND UREASE INHIBITORS Administration of modified Schaedler flora (ASF), that consisted of a specific assemblage of eight bacteria with decreased

abundance of bacteria containing urease gene resulted in a gradual decrease in ammonia production and fecal urease activity. ASF transplantation was also linked to lower morbidity and death

in a mouse model of acute and chronic liver injury77. Urease inhibitors have emerged as an important strategy for reducing ammonia by targeting the synthesis of ammonia by urease bacteria.

Acetohydroxamic acid (AHA) is a well-researched compound that inhibits the enzyme urease. It has been suggested as a therapy for chronic urinary infections caused by the breakdown of urea78.

Apart from AHA, other potent urease inhibitors, such as octanohydroxamic acid (OHA) and nicotinohydroxamic acid, have been studied as potential therapies for HE. In a recent study,

2-octynohydroxamic acid, a urease inhibitor exhibited minimal cytotoxic and carcinogenic effects at micromolar concentrations and also decreased ammonia levels in mouse models of both acute

and chronic liver disease79. However, more evidences that urease inhibitors are effective in liver disease are still lacking. CONCLUSION AND FUTURE PERSPECTIVES Ammonia is the most common

source of nitrogen available in the gut and given the fact that many microbial species produce and use ammonia in their metabolic processes, they play a crucial role in maintaining blood

ammonia levels. Although meager, available experimental evidence strongly suggest that the intestinal microbiota is actively involved in the synthesis and breakdown of ammonia along with the

host cells in liver physiology and pathophysiology. It is thus important to consider the contribution of gut microbiome towards ammonia production and systemic levels during liver disease.

Different animal and patient studies have yielded varying results as the net result of gut microbial ammonia metabolism to plasma ammonia levels from a quantitative perspective varies

according to many parameters like the nutritional status, liver disease severity, the animal model studied, the availability of the nitrogen sources, the composition and concentration of the

microbiota, the overall metabolic capacity of the microbiota, the bowel transit time, the luminal pH, systemic glutamine levels, etc. Nonetheless, the effectiveness of many gut

microbiota-targeted therapies in reducing hyperammonemia and cognitive impairments in cirrhosis affirms a key role of gut microbiome in ammonia production and utilization. We now need

systematic investigations to delineate the precise contribution and mechanisms of increased ammonia production by gut microbial species to hyperammonemia in cirrhosis and HE.

Microbiome-targeted therapy for lowering of ammonia levels in patients with HE has made substantial progress in last few years. However, the routine use of these generalized therapies such

as FMT and antibiotics can also disrupt the beneficial effects of intestinal flora. In this regard, we need to focus on therapies that specifically reduce ammonia formation in patients with

cirrhosis, for example targeting bacterial urease activity would be an ideal strategy to reduce ammonia production in a dysbiotic gut in cirrhosis. DATA AVAILABILITY No datasets were

generated or analysed during the current study. REFERENCES * Rowland, I. et al. Gut microbiota functions: metabolism of nutrients and other food components. _Eur. J. Nutr._ 57, 1–24 (2018).

Article  CAS  PubMed  Google Scholar  * Tranah, T. H. et al. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients

with cirrhosis. _J. Hepatol._ 77, 1554–1563 (2022). Article  CAS  PubMed  Google Scholar  * Allen, W. J. & Collinson, I. A molecular dual carriageway. _eLife_ 9, e61148 (2020). * Cagnon,

L. & Braissant, O. Hyperammonemia-induced toxicity for the developing central nervous system. _Brain Res. Rev._ 56, 183–197 (2007). Article  CAS  PubMed  Google Scholar  * Levitt, D. G.

& Levitt, M. D. A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion

of ammonia in humans. _Clin. Exp. Gastroenterol._ 11, 193–215 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ling, Z.-N. et al. Amino acid metabolism in health and disease.

_Signal Transduct. Target. Ther._ 8, 1–32 (2023). Google Scholar  * Rose, C. F. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. _Clin. Pharmacol. Ther._ 92, 321–331

(2012). Article  CAS  PubMed  Google Scholar  * Romero-Gómez, M. et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.

_J. Hepatol._ 41, 49–54 (2004). Article  PubMed  Google Scholar  * Wright, G., Noiret, L., Olde Damink, S. W. M. & Jalan, R. Interorgan ammonia metabolism in liver failure: the basis of

current and future therapies. _Liver Int. Off. J. Int. Assoc. Study Liver_ 31, 163–175 (2011). Article  CAS  Google Scholar  * Weiner, I. D. & Verlander, J. W. Renal Ammonia Metabolism

and Transport. _Compr. Physiol._ 3, 201–220 (2013). Article  PubMed  PubMed Central  Google Scholar  * Baertl, J. M., Sancetta, S. M. & Gabuzda, G. J. Relation of acute potassium

depletion to renal ammonium metabolism in patients with cirrhosis. _J. Clin. Investig._ 42, 696–706 (1963). Article  CAS  PubMed  PubMed Central  Google Scholar  * Katayama, K. & Kakita,

N. Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so-called latency period of abnormal ammonia metabolism. _Hepatol. Res. Off. J. Jpn.

Soc. Hepatol._ 54, 235–243 (2024). Article  CAS  Google Scholar  * Eriksen, P. L., Djernes, L., Vilstrup, H. & Ott, P. Clearance and production of ammonia quantified in humans by

constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. _J. Hepatol._ 79, 340–348 (2023). Article  CAS  PubMed  Google Scholar  * Dejong, C. H., Deutz, N. E.

& Soeters, P. B. Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. _J. Clin. Investig._ 92, 2834–2840 (1993). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Cooper, A. J., Nieves, E., Coleman, A. E., Filc-DeRicco, S. & Gelbard, A. S. Short-term metabolic fate of [13N]ammonia in rat liver in vivo. _J. Biol.

Chem._ 262, 1073–1080 (1987). Article  CAS  PubMed  Google Scholar  * Nomura, F. et al. Effect of intrahepatic portal-systemic shunting on hepatic ammonia extraction in patients with

cirrhosis. _Hepatol. Baltim. Md_ 20, 1478–1481 (1994). Article  CAS  Google Scholar  * Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its

complications. _J. Hepatol._ 60, 940–947 (2014). Article  CAS  PubMed  Google Scholar  * Chen, Z. et al. The role of intestinal bacteria and gut–brain axis in hepatic encephalopathy. _Front.

Cell. Infect. Microbiol_. 10, 595759 (2021). * Olde Damink, S. W. M. et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with

cirrhosis. _Hepatology_ 37, 1277–1285 (2003). Article  PubMed  Google Scholar  * Moorman, A. F., Vermeulen, J. L., Charles, R. & Lamers, W. H. Localization of ammonia-metabolizing

enzymes in human liver: ontogenesis of heterogeneity. _Hepatology_ 9, 367–372 (1989). Article  CAS  PubMed  Google Scholar  * Matsumoto, S. et al. Urea cycle disorders—update. _J. Hum.

Genet._ 64, 833–847 (2019). Article  PubMed  Google Scholar  * Leung, D. W., Loo, D. D. F., Hirayama, B. A., Zeuthen, T. & Wright, E. M. Urea transport by cotransporters. _J. Physiol._

528, 251–257 (2000). Article  CAS  PubMed  PubMed Central  Google Scholar  * Häussinger, D. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular

glutamine cycle during ureogenesis in perfused rat liver. _Eur. J. Biochem._ 133, 269–275 (1983). Article  PubMed  Google Scholar  * He, Y. et al. Glutamine synthetase in muscle is required

for glutamine production during fasting and extrahepatic ammonia detoxification. _J. Biol. Chem._ 285, 9516 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Suárez, I.,

Bodega, G. & Fernández, B. Glutamine synthetase in brain: effect of ammonia. _Neurochem. Int._ 41, 123–142 (2002). Article  PubMed  Google Scholar  * Weiler, C. T., Nyström, B. &

Hamberger, A. Glutaminase and glutamine synthetase activity in synaptosomes, bulk-isolated glia and neurons. _Brain Res._ 160, 539–543 (1979). Article  CAS  PubMed  Google Scholar  * Owen,

E. E. & Robinson, R. R. Amino acid extraction and ammonia metabolism by the human kidney during the prolonged administration of ammonium chloride*. _J. Clin. Investig._ 42, 263–276

(1963). Article  CAS  PubMed  PubMed Central  Google Scholar  * Lykke Eriksen, P. et al. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. _Clin.

Res. Hepatol. Gastroenterol._ 43, 551–560 (2019). Article  PubMed  Google Scholar  * Rudman, D. et al. Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects. _J.

Clin. Invest._ 52, 2241–2249 (1973). Article  CAS  PubMed  PubMed Central  Google Scholar  * Hamberg, O., Nielsen, K. & Vilstrup, H. Effects of an increase in protein intake on hepatic

efficacy for urea synthesis in healthy subjects and in patients with cirrhosis. _J. Hepatol._ 14, 237–243 (1992). Article  CAS  PubMed  Google Scholar  * Desjardins, P., Rao, K. V.,

Michalak, A., Rose, C. & Butterworth, R. F. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. _Metab. Brain Dis._

14, 273–280 (1999). Article  CAS  PubMed  Google Scholar  * Di Cola, S. et al. Ammonia and the muscle: an emerging point of view on hepatic encephalopathy. _J. Clin. Med._ 11, 611 (2022).

Article  PubMed  PubMed Central  Google Scholar  * Kim, G., Kang, S. H., Kim, M. Y. & Baik, S. K. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and

meta-analysis. _PloS One_ 12, e0186990 (2017). Article  PubMed  PubMed Central  Google Scholar  * Biolo, G., Zorat, F., Antonione, R. & Ciocchi, B. Muscle glutamine depletion in the

intensive care unit. _Int. J. Biochem. Cell Biol._ 37, 2169–2179 (2005). Article  CAS  PubMed  Google Scholar  * Tateyama, M. et al. Loss of skeletal muscle mass affects the incidence of

minimal hepatic encephalopathy: a case control study. _BMC Gastroenterol_ 20, 371 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ganda, O. P. & Ruderman, N. B. Muscle

nitrogen metabolism in chronic hepatic insufficiency. _Metabolism_ 25, 427–435 (1976). Article  CAS  PubMed  Google Scholar  * Laubenberger, J. et al. Proton magnetic resonance spectroscopy

of the brain in symptomatic and asymptomatic patients with liver cirrhosis. _Gastroenterology_ 112, 1610–1616 (1997). Article  CAS  PubMed  Google Scholar  * Butterworth, R. F. Hepatic

encephalopathy in cirrhosis: pathology and pathophysiology. _Drugs_ 79, 17–21 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  * Nowicki, C. et al. Comparison of gut microbiome

composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples. _Front. Microbiol._ 14, 1148097 (2023). Article  PubMed  PubMed Central  Google Scholar  * Wu,

M. et al. The differences between luminal microbiota and mucosal microbiota in mice. _J. Microbiol. Biotechnol._ 30, 287–295 (2020). * Stojic, J., Kukla, M. & Grgurevic, I. The

intestinal microbiota in the development of chronic liver disease: current status. _Diagnostics_ 13, 2960 (2023). Article  CAS  PubMed  PubMed Central  Google Scholar  * Guinane, C. M. &

Cotter, P. D. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. _Ther. Adv. Gastroenterol._ 6, 295–308 (2013). Article 

Google Scholar  * Collins, C. M. & D’Orazio, S. E. Bacterial ureases: structure, regulation of expression and role in pathogenesis. _Mol. Microbiol._ 9, 907–913 (1993). Article  CAS 

PubMed  Google Scholar  * Dintzis, R. Z. & Hastings, A. B. The effect of antibiotics on urea breakdown in mice. _Proc. Natl. Acad. Sci. USA._ 39, 571–578 (1953). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Yu, L. et al. Physiological functions of urea transporter B. _Pflugers Arch_ 471, 1359–1368 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Chang, Y., Park, T.-E., Lee, S.-W. & Lee, E.-H. Colorimetric detection of urease-producing microbes using an ammonia-responsive flexible film sensor. _Biosensors_ 12, 886 (2022). Article

  CAS  PubMed  PubMed Central  Google Scholar  * Mora, D. & Arioli, S. Microbial urease in health and disease. _PLoS Pathog_ 10, e1004472 (2014). Article  PubMed  PubMed Central  Google

Scholar  * Bajaj, J. S. et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. _Am. J. Physiol.

Gastrointest. Liver Physiol._ 303, G675–G685 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang, P. et al. Gut microbiome-derived ammonia modulates stress vulnerability in

the host. _Nat. Metab._ 5, 1986–2001 (2023). Article  CAS  PubMed  Google Scholar  * Kowalchuk, G. A. & Stephen, J. R. Ammonia-oxidizing bacteria: a model for molecular microbial

ecology. _Annu. Rev. Microbiol._ 55, 485–529 (2001). Article  CAS  PubMed  Google Scholar  * Caminero, A., Guzman, M., Libertucci, J. & Lomax, A. E. The emerging roles of bacterial

proteases in intestinal diseases. _Gut Microbes_ 15, 2181922 (2023). * Kang, D. J. et al. Gut microbiota drive the development of neuro-inflammatory response in cirrhosis. _Hepatol. Baltim.

Md_ 64, 1232–1248 (2016). Article  CAS  Google Scholar  * Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. _Hepatology_ 54, 562 (2011).

Article  PubMed  Google Scholar  * Patidar, K. R. & Bajaj, J. S. Covert and overt hepatic encephalopathy: diagnosis and management. _Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J.

Am. Gastroenterol. Assoc._ 13, 2048–2061 (2015). Google Scholar  * Kim, S.-E. et al. The role of gut dysbiosis in acute-on-chronic liver failure. _Int. J. Mol. Sci._ 22, 11680 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar  * Kim, J. N. et al. Metabolic networks for nitrogen utilization in Prevotella ruminicola 23. _Sci. Rep._ 7, 7851 (2017). Article  PubMed

  PubMed Central  Google Scholar  * Li, L., Chen, L., Shang, R., Wang, G. & Zhang, J. Improvement in bioconversion efficiency and reduction of ammonia emission by introduction of fruit

fermentation broth in a black soldier fly larvae and kitchen waste conversion system. _Insect Sci_ 30, 975–990 (2023). Article  CAS  PubMed  Google Scholar  * Kanamori, K., Weiss, R. L.

& Roberts, J. D. Ammonia assimilation pathways in nitrogen-fixing Clostridium kluyverii and Clostridium butyricum. _J. Bacteriol._ 171, 2148–2154 (1989). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Zhan, T. & Stremmel, W. The diagnosis and treatment of minimal hepatic encephalopathy. _Dtsch. Ärztebl. Int._ 109, 180–187 (2012). PubMed  PubMed Central 

Google Scholar  * Liu, Q. et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. _Hepatology_ 39, 1441–1449 (2004). Article  PubMed 

Google Scholar  * Zhang, Z. et al. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. _Am. J. Gastroenterol._ 108, 1601–1611 (2013). Article  CAS 

PubMed  Google Scholar  * Fijan, S. Microorganisms with claimed probiotic properties: an overview of recent literature. _Int. J. Environ. Res. Public. Health_ 11, 4745–4767 (2014). Article 

PubMed  PubMed Central  Google Scholar  * Elkington, S. G., Floch, M. H. & Conn, H. O. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical

trial. _N. Engl. J. Med._ 281, 408–412 (1969). Article  CAS  PubMed  Google Scholar  * Fritz, E. et al. Effects of lactulose and polyethylene glycol on colonic transit. _Aliment. Pharmacol.

Ther._ 21, 259–268 (2005). Article  CAS  PubMed  Google Scholar  * Riggio, O. et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. _J. Clin.

Gastroenterol._ 12, 433 (1990). Article  CAS  PubMed  Google Scholar  * Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent

exposure in healthy humans. _Sci. Transl. Med._ 11, eaau7975 (2019). Article  CAS  PubMed  Google Scholar  * Ochoa-Sanchez, R. et al. Genetically engineered E. coli Nissle attenuates

hyperammonemia and prevents memory impairment in bile-duct ligated rats. _Liver Int. Off. J. Int. Assoc. Study Liver_ 41, 1020–1032 (2021). CAS  Google Scholar  * Nicaise, C. et al. Control

of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. _Hepatology_ 48, 1184–1192 (2008). Article  CAS  PubMed  Google

Scholar  * Greenberg, L. H. & Momary, H. Audiotoxicity and nephrotoxicity due to orally administered neomycin. _JAMA_ 194, 827–828 (1965). Article  CAS  PubMed  Google Scholar  * Tarao,

K. et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. _Gut_ 31, 702–706 (1990). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Nakai, M. et al. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. _PLoS One_ 17, e0270786 (2022). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Loguercio, C., Federico, A., De Girolamo, V., Ferrieri, A. & Del Vecchio Blanco, C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin.

Results of a double-blind clinical study. _Minerva Gastroenterol. Dietol._ 49, 53–62 (2003). CAS  PubMed  Google Scholar  * Yu, X. et al. Rifaximin modulates the gut microbiota to prevent

hepatic encephalopathy in liver cirrhosis without impacting the resistome. _Front. Cell. Infect. Microbiol._ 11, 761192 (2022). Article  PubMed  PubMed Central  Google Scholar  * Kassam, Z.

et al. Donor screening for fecal microbiota transplantation. _N. Engl. J. Med._ 381, 2070–2072 (2019). Article  PubMed  Google Scholar  * Bajaj, J. S. et al. Fecal microbiota transplant from

a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. _Hepatology_ 66, 1727–1738 (2017). Article  CAS  PubMed  Google Scholar  * Shawcross, D. et al. Faecal

microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial. Preprint at

https://doi.org/10.21203/rs.3.rs-3088449/v1 (2023). * Shen, T.-C. D. et al. Engineering the gut microbiota to treat hyperammonemia. _J. Clin. Invest._ 125, 2841–2850 (2015). Article  PubMed

  PubMed Central  Google Scholar  * Griffith, D. P. & Musher, D. M. Acetohydroxamic acid. potential use in urinary infection caused by urea-splitting bacteria. _Urology_ 05, 299–302

(1975). Article  CAS  PubMed  Google Scholar  * Evstafeva, D. et al. Inhibition of urease-mediated ammonia production by 2-octynohydroxamic acid in hepatic encephalopathy. _Nat. Commun._ 15,

2226 (2024). Article  CAS  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS The figures have been created using BioRender.com. AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India Deepika Jakhar & Savneet Kaur * Department of Hepatolopgy,

Institute of Liver and Biliary Sciences, New Delhi, India Shiv K. Sarin Authors * Deepika Jakhar View author publications You can also search for this author inPubMed Google Scholar * Shiv

K. Sarin View author publications You can also search for this author inPubMed Google Scholar * Savneet Kaur View author publications You can also search for this author inPubMed Google

Scholar CONTRIBUTIONS D.J. and S.K. conceived the study and drafted the manuscript. D.J. designed the figures. S.K.S. and S.K. revised the manuscript. All authors read and approved the final

manuscript. CORRESPONDING AUTHOR Correspondence to Savneet Kaur. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as

long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not

have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s

Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

http://creativecommons.org/licenses/by-nc-nd/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jakhar, D., Sarin, S.K. & Kaur, S. Gut microbiota and dynamics of ammonia

metabolism in liver disease. _npj Gut Liver_ 1, 11 (2024). https://doi.org/10.1038/s44355-024-00011-x Download citation * Received: 15 July 2024 * Accepted: 11 October 2024 * Published: 04

December 2024 * DOI: https://doi.org/10.1038/s44355-024-00011-x SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative